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Summary The N2 slope is an index of inhomogeneous distribution of ventilation
and has been suggested to be suited for early testing of chronic obstructive
pulmonary disease (COPD) in smokers. The aim of the present study was to examine
the association between the fraction of exhaled nitric oxide (FENO) and the N2 slope
in a random population of smoking and non-smoking men. Altogether 57 subjectsee front matter & 2005
med.2005.09.037
ng author. Tel.: +46 31
ess: anna-carin.olin@ymwere included in the study, 24 never-smokers, seven ex-smokers and 26 current
smokers. Subjects were examined twice, in 1995 when they regarded themselves as
healthy, and in a follow-up in 2001. Spirometry, N2 slope and high-resolution
computed tomography (HRCT) were performed in 1995 while the follow-up
examination included also measurement of FENO.
The FENO value was significantly lower and the N2 slope higher in current
smokers. In smokers but not in never- or ex-smokers FENO was correlated to the
difference in N2 slope between 1995 and 2001 (rs ¼ 0:49, P ¼ 0:01). We analysed the
data by multiple linear regression adjusted for smoking, mild respiratory symptoms
and inhaled steroids. There were significant associations between FENO and the N2
slope both in 1995 and in 2001. The strongest association was found to exist with the
change in N2 slope during these years.
Sixteen of the subjects could be classified as having COPD, six with mild and ten
with moderate COPD. There was a trend for an increase in N2 slope with increased
severity of COPD; among subjects with no COPD the N2 slope in 2001 was 2.3% N2/L,
and those with mild and moderate COPD had 2.5% N2/L and 3.9% N2/L, respectively
(P ¼ 0:0004). No such trend was seen for FENO (17.8, 15.5 and 20.3 parts per billion
(ppb), respectively, P ¼ 0:8).
The results show that FENO is associated with the N2 slope, indicating that FENO
reflects inflammatory changes in the peripheral airways of both non-smoking and
smoking subjects.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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A.-C. Olin et al.1014Background present study we have therefore examined theThere is increasing evidence to suggest that the
fraction of exhaled nitric oxide (FENO) can be used
as a marker for airway inflammation, at least in
allergic asthma. Accordingly FENO has so far been
used mainly in studies of asthma, including a few
studies exploiting its ability to predict exacerba-
tions of asthma.1,2 In studies of chronic obstructive
pulmonary disease (COPD) the usefulness of FENO is
more ambiguous3 while smoking has been reported
to lower FENO.4,5 A number of studies6–8 have
shown that patients with COPD have a lower FENO
than do healthy individuals and that smoking status
highly influences FENO levels. Among ex-smoking
subjects; however, those with COPD have higher
FENO levels than those without COPD.9 The FENO
value has also been shown to increase during
exacerbations of COPD9,10 and to be correlated to
neutrophils in induced sputum among patients with
COPD,11 indicating that the method potentially has
value in monitoring COPD, at least in non-smoking
subjects.
Smokers have a lower FENO than do non-
smokers.5 Directly after smoking a cigarette there
is, however, an increase in FENO lasting for at least
10min12 and probably due to the high contents of
nitric oxide (NO) in inhaled smoke. Smoking
cessation is associated with an increase in FENO,
though FENO levels have been found to be lower
among ex-smokers than among never-smokers still
8 weeks after quitting smoking.13 Experimental
studies have shown that it is mainly endothelial NO
synthase (eNOS) that is irreversibly inhibited by
cigarette smoke.14,15
The slope of the single-breath N2 test (the N2
slope) is an index of inhomogeneous or asynchro-
nous intra-pulmonary ventilation distribution.16–18
The N2 slope has been shown to be more sensitive
than spirometric variables for detecting tobacco
smoke-induced changes in the lungs.19,20 In studies
relating structural changes to lung function tests
among smokers it has been found that the N2 slope
is related to inflammatory changes in the periph-
eral airways.21 Furthermore, the N2 slope has been
shown to be predictive of the decline of forced
expiratory volume in 1 s (FEV1) in smokers.
22 The
predictive value of the N2 slope used in combina-
tion with spirometry has also been shown by
Stanescu et al. (1998).23 There is therefore
increasing evidence suggesting that the N2 slope,
in particular in combination with spirometry, may
be useful as an early test for COPD.
As FENO is a marker of airway inflammation, we
hypothesised that it may be an early marker in
COPD when smoking habit is adjusted for. In therelation between FENO levels and the N2 slope in a
population sample of 57 men born in 1933 in
Gothenburg, Sweden.Materials and methods
Study population
The subjects were recruited from an earlier study
on a random population sample titled, ‘‘Men born
in 1933 in Go¨teborg’’.24 From the original cohort of
879 men a random sample of 92 men (58 current
smokers and 34 non-smokers) were investigated in
1995 concerning emphysematous lesions25 and
inflammatory markers.26 The FENO value was,
however, not obtained at that investigation. At
the time the subjects all regarded themselves as
healthy and did not report previous medical
consultations for respiratory symptoms.
The present study is a follow-up study of those 92
men who were investigated in 1995. Altogether 67
subjects attended the follow-up study, giving a
participation rate of 73%. Ten subjects were
excluded because of missing NO values (seven due
to equipment failure and three due to failure to
perform acceptable NO measurements). One of the
excluded subjects also failed to perform the N2
test. Hence, the final number of subjects included
in the present study was 57.
Subjects were divided into current smokers, ex-
smokers and never-smokers at follow-up. Current
smokers included also those three subjects who had
stopped smoking during the previous 12 months.
The current smokers had smoked for 51 years on
average while the ex-smokers had smoked for an
average of 37 years. Basic data on the subjects are
presented in Table 1.
Examination
Exhaled NO was measured using the Ecophysics
Breath Analyzer CLD 700 AL chemiluminescence
analyser (Switzerland). A special computer bio-
feedback system was used to regulate exhalation
flow rate (Exhalation Breath Analyzer
TM
; Aerocrine
AB, Stockholm, Sweden). Two-point calibration of
the analyser was performed daily with a certified
NO calibration gas. The exhaled NO was measured
during a slow single exhalation for 20 s against an
oral pressure of 5 cm H2O at a constant flow rate of
50ml/s (710%) in accordance with American
Thoracic Society (ATS) recommendations.27 The
measurements were performed in triplicate on
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Table 1 Mean (7 standard deviation, SD) subject data for 2001.
Never-smokers Ex-smokers Current smokers
n 24 7 26
BMI (kg/m2) 27.0 (2.7) 28.0 (2.0) 25.4 (3.4)
FEV1 (%) 103 (14) 91 (14) 88 (21)
FVC (%) 105 (15) 99 (11) 100 (18)
DLCO (%) 98 (14) 99 (19) 79 (18)
Mild respiratory symptomsa 6 (25%) 3 (43%) 15 (58%)
Asthma 1 (4%) 0 1 (4%)
DLCO ¼ diffusing capacity of the lung for carbon monoxide; FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital capacity.
FEV1, FVC and DLCO are expressed as a percentage of the predicted normal values.
aCurrent wheeze, cough or dyspnoea.
Single breath N2-test and exhaled nitric oxide in men 1015each occasion and the mean concentration, in parts
per billion (ppb), during the plateau phase was
registered.
The subjects underwent spirometry with a water-
sealed spirometer, according to European Respira-
tory Society (ERS) guidelines.28 Vital capacity (VC)
was measured and FEV1 was registered and its
percentage of the VC (FEV%) obtained. The diffus-
ing capacity of the lung for carbon monoxide (DLCO)
was assessed by the single-breath method using
standard equipment (Sensor Medics 2200, Sensor
Medics Corporation, The Netherlands). The slope of
the alveolar plateau (i.e. the N2 slope) was
obtained by the single-breath N2 method.
29 In the
following the results from the measurements in
1995 and 2001 are presented, as is the difference in
N2 slope (i.e. N
2001
2  N19952 ). Predicted normal
values for VC, FEV1 and FEV% were calculated
according to a local reference material,30 while
DLCO was measured according to Salorinne
31 and
for the N2 slope according to Sixt et al.
32
High-resolution computed tomography (HRCT)
was used and evaluated as previously described33
in all subjects. In brief, the diagnosis of emphyse-
matous lesions was based on the findings of areas
with low attenuation and/or presence of stretched
narrow vessels. Severity of emphysematous changes
was scored on a four-point scale ranging from 0 to 3,
where 0 was equivalent to no emphysema. Ground-
glass attenuation was defined as slightly hyper-
attenuating areas in which underlying vessels and
bronchial walls remained visible. All subjects
completed a respiratory questionnaire with items
similar to those of previous questionnaires.34Statistical methods
The statistical analyses of the categorical data
were based on the w2 test. As the NO data were not
normally distributed they were analysed with non-parametric methods (Kruskal-Wallis), but group
means are presented. P-values have usually been
provided. Correlations were tested using Spear-
man’s rank correlation coefficient. The associations
between the log-transformed values of exhaled NO
and different explanatory variables (smoking,
height, use of inhaled glucocorticoids, asthma
symptoms and N2 slope at follow-up) were tested
using multiple linear regression models. The sig-
nificance of the slope in the multivariate regression
model was based on the t distribution. For the
linear regression models, PROC REG in the SAS
statistical package (release 8.0; SAS Instituted,
Cary, NC, USA) was used.Results
The FENO value in relation to smoking status is
presented in Fig. 1. The FENO values were
significantly lower among current smokers than in
never-smokers and tended to be higher among ex-
smokers (n ¼ 7) than among the never-smoking
subjects but the difference was not statistically
significant.
FENO, N2 slope for 1995 and 2001, and the
change in N2 slope are presented in Table 2. FENO
was significantly lower and the N2 slope higher
among the current smokers. Among the never-
smokers and ex-smokers there was no association
between FENO and the N2 slope in 1995 or 2001; nor
was there an association between the FENO value
and the change in N2 slope (Fig. 2a). Among the
current smokers there was a significant association
between FENO values and the change in N2 slope
from 1995 to 2001 (rs ¼ 0:49, P ¼ 0:01) (Fig. 2b),
but not between FENO and the single N2 slope in
either 1995 or 2001. When analysing the data by
multiple linear regression adjusted for smoking,
height, mild respiratory symptoms and inhaled
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tween FENO values and the N2 slope for 2001
(estimate 0.13, P ¼ 0:051). The strongest associa-
tion was found with the change in N2 slope (see
Table 3). The latter model included the result for
the N2 slope in 1995, thereby weighting the change
in N2 slope to the initial value.
The seven ex-smokers had the highest FENO
levels (24.1 ppb) and the largest change in N2 slope
from 1995 to 2001 (1.39% N2/L), compared with
never-smokers (19.0 ppb and 0.28% N2/L) and
smokers (15.4 ppb and 0.45% N2/L).
According to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria,35 16 of
the subjects could be classified as having COPD, six
(one never-smoker, one ex-smoker and four current
smokers) with mild and ten (one ex-smoker and
nine current smokers) with moderate COPD. There
was a trend for an increasing N2 slope with
increasing severity of COPD; among subjects with
no COPD the N2 slope in 2001 was 2.3% N2/L; those
with mild and moderate COPD had 2.5% N2/L and
3.9% N2/L, respectively (P ¼ 0:0004). There was no
such trend for FENO (17.8, 15.5 and 20.3 ppb,
respectively, P ¼ 0:8).Table 2 Results of the N2 test for 1995 and 2001, differ
oxide (NO), according to smoking habit (means and inter-
Never-smokers
N 24
N2 test 1995
a 1.4 (1.0–1.7)
N2 test 2001
a 1.7 (1.4–2.4)
Difference in N2 test (2001–1995)
a 0.3 (0–0.6)
Exhaled NO 2001 (ppb) 19.0 (12.8–24.
ppb ¼ parts per billion.
a% N2/ L.
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Figure 1 Exhaled nitric oxide (NO), (ppb), in relation to
smoking status, in box-plots representing maximum and
minimum values, 25th and 75th percentiles and medians.There was no association between FENO and
FEV1, or FENO and change in FEV1 from 1995 to
2001, nor did analyses of the data for the group as a
whole or analyses stratified according to smoking
status reveal any associations. Similarly, HRCT
showed no association between FENO and emphy-
sema, or progress of emphysematous lesions,
between 1996 and 2001.
Six non-smokers (three never-smokers and three
ex-smokers) were classified as having ground-glass
attenuation, as demonstrated by HRCT. In this
group neither the N2 slope nor the change in N2
slope was different from those without ground-
glass attenuation (0.52% vs. 0.56% N2/L, P ¼ 0:8).
There was also no significant difference in FENO
value between the groups (18.0 vs. 20.7 ppb,
P ¼ 0:33) or in FEV1 or FVC. In the small group of
subjects with ground-glass attenuation the correla-
tion between the change in N2 slope from 1995 to
2001 and exhaled NO measured in 2001 was,
however, stronger (rs ¼ 0:89, P ¼ 0:02).Discussion
The main result of the present study is that an
association was found to exist between FENO and
deterioration of the N2 slope over a 6-year period in
a group of never-, ex- and current smokers when
adjusting for smoking status. In a multiple regres-
sion model, FENO was associated with the dete-
rioration of the N2 test over six years while the
results from the last N2 test in 2001 were not
significantly associated with FENO. The reason for
this is unclear but one plausible explanation may be
that the deterioration of the N2 slope is a stronger
indicator of an ongoing inflammatory process than
is the single last measurement of the N2 slope.
The FENO value for ex-smokers, 24.1 ppb (range
12.4–38.6), was slightly but not significantly higher
than that for the never-smokers, 19.0 ppb
(4.6–39.5), indicating that the suppressive effect
of previous smoking on FENO had ceased. In theence between the two test results, and exhaled nitric
quartile range).
Ex-smokers Current smokers
7 26
1.7 (0.8–2.1) 2.7 (1.8–3.7)
3.1 (1.6–4.3) 3.2 (2.5–3.7)
1.4 (0.4–2.2) 0.5 (0.1–1.0)
4) 24.1 (14.9–30.4) 15.4 (9.8–20.3)
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Table 3 Variables included in a multiple linear regression model, with logarithm- transformed fraction of
exhaled nitric oxide (FENO) as the dependent variable.
Variable Estimate SEM P-value
Intercept 2.67 0.16 0.6
Smoking
Never-smokera 0.05 0.24 0.8
Current smokera 0.41 0.24 0.09
Height (cm) 0.02 0.01 0.07
Asthma-like symptomsa 0.15 0.14 0.3
Current use of inhaled steroidsa 0.42 0.53 0.4
N2 test, 1995
b 0.15 0.085 0.08
Difference between N2 test results of 1995 and 2001
b 0.22 0.098 0.03
SEM ¼ standard error of the mean.
aYes ¼ 1, no ¼ 0.
b% N2/L.
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Figure 2 (a) Fraction of exhaled nitric oxide (FENO), in parts per billion (ppb), and change in the N2 slope between 1995
and 2001 among never-smokers (m) and ex-smokers ( ). Spearman’s rank correlation coefficient for never-smokers
rs ¼ 20:06, P ¼ 0:77, and for ex-smokers rs ¼ 0:46, P ¼ 0:23. (b) Fraction of exhaled nitric oxide (FENO), in parts per
billion (ppb), and change in N2 slope between 1995 and 2001 among current smokers. Spearman’s rank correlation
coefficient rs ¼ 0:49, P ¼ 0:01.
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ported treatment with inhaled glucocorticoids.
Their FENO values were 30.3 and 39.5 ppb, respec-
tively.
In the literature there is only one previous study
on FENO and N2 slope.
36 In that study FENO was
reported to be related to the N2 slope (rs ¼ 0:54,
P ¼ 0:032) in a cross-sectional study of 16 subjects
with intermittent or mild asthma. The authors
concluded that FENO was reflecting small airway
dysfunction in asthma and may be complementary
to spirometry to monitor asthma.
The N2 slope is suggested to reflect an inhomo-
geneous distribution of ventilation, which may
result from either inflammatory processes or
structural changes in the airways. Inhomogeneous
ventilation may also affect the FENO levels per se,
since in segments of the lung with low intra-
bronchial flow the air has more time to be
saturated with NO, leading to increased exhaled
NO concentrations. On the other hand, to reach the
predicted exhalation flow the airflow in other parts
of the bronchial tree must be higher, causing a
lower concentration of NO in these segments. The
net result on the exhaled NO concentration is
unclear.
Ground-glass attenuation is related to various
patho-anatomical changes in the airways of smo-
kers, such as partial filling of air spaces, inflamma-
tory or fibrotic interstitial thickening or increased
capillary blood volume. In the few subjects with
ground-glass attenuation in this study the N2 slope
was not increased nor the FENO levels and they had
normal spirometry. On the other hand, in subjects
who had ground-glass attenuation the association
between FENO and N2 slope was strong (rs ¼ 0:89,
P ¼ 0:02).
An analysis of the drop-outs in the follow-up
study has been performed. Among the subjects who
were never-smokers in 1995, the participating and
non-participating subjects were quite similar.
Among the current smokers the non-participating
subjects had lower FEV1 and FVC compared with
the participating subjects. However, the N2 slope of
the non-participating subjects was 2.57, as com-
pared with 2.97 for the participating subjects
(P ¼ 0:43). Consequently we do not consider the
selection bias to have influenced the results to any
significant degree.
Whether a rise in FENO is beneficial or has
detrimental effects in ex-smokers, such as in four
out of seven ex-smokers in this study, is unclear. In
other diseases increasing evidence has been pre-
sented indicating favourable effects of increased
NO production. An important function appears to
be that NO has the potential to act as a scavengerand bind more aggressive free radicals. In COPD, in
which there is an excess of free radicals, such a
scavenger would fulfil an important function. It is,
however, uncertain to what extent FENO reflects
the actual production of NO in the micro-environ-
ment, as the locally produced NO may be largely
scavenged by neutrophil-derived radicals.
In conclusion, the results indicate that measure-
ment of FENO can reflect inflammatory changes in
the peripheral airways of non-smokers, ex-smokers
and current smokers. The clinical implication of
this is still unclear. Whether FENO can add valuable
information to the slope of the N2 test, enabling a
better prediction of COPD, is of interest for future
studies.
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